These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8394651)

  • 21. The interaction of clozapine with the meta-chlorophenylpiperazine (mCPP) discriminative stimulus.
    Fiorella D; Rabin RA; Winter JC
    Life Sci; 1996; 58(24):PL353-8. PubMed ID: 8649203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonin receptor responsivity in schizophrenia.
    Kahn RS; Davidson M
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():47-51. PubMed ID: 7911140
    [No Abstract]   [Full Text] [Related]  

  • 23. The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine.
    Meltzer HY; Maes M; Lee MA
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S95-104. PubMed ID: 7831446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms.
    Krystal JH; Webb E; Cooney N; Kranzler HR; Charney DS
    Arch Gen Psychiatry; 1994 Nov; 51(11):898-911. PubMed ID: 7944878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia.
    Schulz E; Fleischhaker C; Remschmidt HE
    J Child Adolesc Psychopharmacol; 1996; 6(2):119-31. PubMed ID: 9231304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects.
    Kahn RS; Wetzler S; Asnis GM; Kling MA; Suckow RF; van Praag HM
    Psychiatry Res; 1991 Apr; 37(1):25-34. PubMed ID: 1650487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of m-chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects.
    Kahn RS; Knott P; Gabriel S; DuMont K; Mastroianni L; Davidson M
    Biol Psychiatry; 1992 Dec; 32(11):1055-61. PubMed ID: 1467386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroendocrine response to meta-chlorophenylpiperazine and ipsapirone in relation to anxiety and aggression.
    Klaassen T; Riedel WJ; van Praag HM; Menheere PP; Griez E
    Psychiatry Res; 2002 Dec; 113(1-2):29-40. PubMed ID: 12467943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients.
    Lindenmayer JP; Adityanjee ; Vital-Herne M; Bark N; Grochowski S; Moynihan N
    Biol Psychiatry; 1997 Jul; 42(1):6-12. PubMed ID: 9193736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study.
    Pitchot W; Wauthy J; Legros JJ; Ansseau M
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):151-5. PubMed ID: 15013031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight gain among schizophrenic patients treated with clozapine.
    Lamberti JS; Bellnier T; Schwarzkopf SB
    Am J Psychiatry; 1992 May; 149(5):689-90. PubMed ID: 1349460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of clozapine on cognitive function in schizophrenia.
    Lee MA; Thompson PA; Meltzer HY
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():82-7. PubMed ID: 7961582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls.
    Koreen AR; Lieberman JA; Alvir J; Chakos M
    Neuropsychopharmacology; 1997 Jan; 16(1):61-8. PubMed ID: 8981389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia.
    Breier A; Kirkpatrick B; Buchanan RW
    Biol Psychiatry; 1993 Oct; 34(7):492-4. PubMed ID: 8268334
    [No Abstract]   [Full Text] [Related]  

  • 38. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia.
    Buchanan RW; Kirkpatrick B; Bryant N; Ball P; Breier A
    Am J Psychiatry; 1996 Dec; 153(12):1625-7. PubMed ID: 8942462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study.
    Kahn RS; Wetzler S; Asnis GM; Kling MA; Suckow RF; van Praag HM
    Psychopharmacology (Berl); 1990; 100(3):339-44. PubMed ID: 2156278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence].
    Fleischhaker C; Schulz E; Remschmidt H
    Z Kinder Jugendpsychiatr Psychother; 1998 Dec; 26(4):235-43. PubMed ID: 9880833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.